Estrella Immunopharma, Inc. Warrant financials
$0.0600−14.29%
Close Sep 23, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Jun 30 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$13.1M | -$7.3M |
| Net income | -$13.1M | -$7.3M |
| Net margin | — | — |
| Diluted EPS | $-0.35 | $-0.27 |
| EBITDA | -$13.1M | -$7.3M |
| Operating cash flow | -$1.8M | -$16.1M |
| Free cash flow | -$1.8M | -$16.1M |
| Diluted shares | 36.8M | 27.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $1.4M | $916.9K |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $3.2M | $3.1M |
| Total liabilities | $13.5M | $3.0M |
| Shareholders' equity | -$10.4M | $143.7K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology